Seignalet C, Préfaut C, Gonzales C, Michel F B
Rev Fr Mal Respir. 1980;8(6):627-33.
A double-blind study was conducted to evaluate the effects of almitrine, administered orally as 3.5 mg/kg/day for one month, when compared with placebo in 20 patients with chronic obstructive pneumopathies from smoking, currently in the stage of chronic hypercapnic respiratory insufficiency. Clinical improvement was obtained, with a reduction in dyspnea and a more comfortable respiration. Objective signs of improvement where enhanced adaptation to assisted ventilation (3 cases out of 5), and less secondary infection in the almitrine group (0/10) than the placebo group (4/10). A statistically significant improvement (p less than 0.01) was recorded in blood oxygen and bicarbonates levels, and to a lesser degree, in blood CO2 levels (p less than 0.05) and without any increase in overall ventilation. As tolerance was good (8/10), almitrine appears to occupy a place of choice in the field of respiratory analeptic therapy. Its efficacy and convenience in use for daily practice require confirmation in long-term studies (more than 6 months).
进行了一项双盲研究，以评估口服氨苯碱（剂量为3.5毫克/千克/天，持续一个月）对20名吸烟所致慢性阻塞性肺病且目前处于慢性高碳酸血症呼吸功能不全阶段患者的影响，并与安慰剂进行比较。结果取得了临床改善，呼吸困难减轻，呼吸更舒适。改善的客观体征包括对辅助通气的适应性增强（5例中有3例），且氨苯碱组的继发感染少于安慰剂组（氨苯碱组0/10，安慰剂组4/10）。血液氧和碳酸氢盐水平有统计学意义的改善（p小于0.01），血液二氧化碳水平也有较小程度的改善（p小于0.05），且总体通气未增加。由于耐受性良好（8/10），氨苯碱在呼吸兴奋治疗领域似乎占据首选地位。其在日常实践中的疗效和使用便利性需要在长期研究（超过6个月）中得到证实。
